<DOC>
	<DOC>NCT00546143</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of omalizumab against asthma attacks in mild to moderate allergic asthma</brief_summary>
	<brief_title>Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Diagnosis of allergic asthma &gt;= 1 year duration and a history consistent with Step 2 or 3 clinical features from the Global Initiative for Asthma guidelines. Eligible baseline serum immunoglobulin E (IgE) levels value and bodyweight combinations Documented medical history of anaphylaxis Lung disease other than mild to moderate allergic asthma such as chronic obstructive pulmonary disease (COPD) Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Asthma, anti-immunoglobulin E, omalizumab</keyword>
</DOC>